Maryland State Retirement & Pension System Buys 11,731 Shares of Charles River Laboratories International, Inc. $CRL

Maryland State Retirement & Pension System raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 440.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,395 shares of the medical research company’s stock after acquiring an additional 11,731 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Charles River Laboratories International were worth $4,247,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after purchasing an additional 54,500 shares in the last quarter. Amundi boosted its position in shares of Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares in the last quarter. Van Berkom & Associates Inc. grew its stake in Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock worth $86,449,000 after purchasing an additional 50,462 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock worth $59,044,000 after purchasing an additional 142,716 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CRL shares. Jefferies Financial Group increased their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a report on Monday, September 28th. Deutsche Bank boosted their target price on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a report on Friday, September 25th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Wall Street Zen raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Finally, Zacks Research lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $311.67.

Read Our Latest Stock Analysis on CRL

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Shannon Parisotto sold 2,156 shares of the business’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares in the company, valued at approximately $410,175.12. This represents a 28.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 63,352 shares of company stock valued at $20,291,281. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $338.27 on Monday. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76. The business’s 50 day moving average price is $311.21 and its 200-day moving average price is $228.24. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $379.63. The stock has a market cap of $16.21 billion, a P/E ratio of 371.73, a P/E/G ratio of 3.05 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The company had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. During the same quarter in the prior year, the business posted $2.43 EPS. The firm’s quarterly revenue was down 2.2% compared to the same quarter last year. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

Further Reading

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.